OUR MISSION:

TO BE A WORLD-CLASS RESEARCH AND EDUCATIONAL ORGANIZATION, DEDICATED TO THE PRESERVATION AND RESTORATION OF VISION.

Your donations help restore sight.

About the Foundation

As a 501(c)3 not for profit founded in 1988, the Cornea Research Foundation of America, is an award winning, internationally recognized research and educational organization, dedicated to the preservation and restoration of vision and known for conducting clinical studies to evaluate new drugs, lasers, devices and treatments. We measure our success based on four pillars: Research, Innovation, Service to Humanity, and Education, summarized in the acronym RISE. Our goal is to continually find new and better ways to give people back the use of their eyes so they can attend school, make a living, and support their family. We share our findings through frequent presentations, publications and medical education courses so that patients throughout the world can benefit from our findings.
A Message from the Executive Director

What an exciting year! Our work has attracted international recognition - we were invited to share our cornea transplant findings at major eye meetings in Europe, Asia and South America. We were fortunate to have two gifted cornea specialists, from leading eye centers in Brazil and Singapore, join us for one-year research fellowships. Dr. Guerra and Dr. Anshu were incredibly productive and their work on improved cornea transplant techniques resulted in 12 publications in leading eye journals. In addition, we were honored to receive the prestigious Santa Caterina d’Oro award for excellence in medical research, at a lovely ceremony held annually in the historic town of Siena, Italy.

We envision a future where corneal problems are detected and treated early, before leading to serious vision loss. We are making steady progress toward this goal by identifying the underlying genetic causes of Fuchs dystrophy. This work should ultimately lead to early detection and innovative treatments. In addition, we are having good results with an investigational corneal strengthening treatment that can help preserve the vision of teenagers and young adults who have a condition known as keratoconus.

Collaborating with other centers around the country, we detected a surprisingly high incidence of antibiotic-resistant bacteria on the surface of the eye and eyelids of patients scheduled for cataract surgery, clearly demonstrating the need for new and improved antibiotics. To help address this need, we are among a select group of centers pioneering the use of an innovative light treatment to kill organisms that cause eye infections. Some of the most serious eye infections occur in young people who wear contact lenses for extended periods of time, and we are finding this treatment to be very helpful for these young folks.

We are proud that Working Vision, the fledgling organization we helped nurture the past several years, has recently taken flight and achieved independent non-profit status. Working Vision is the brainchild of Grant Moore, one of our former summer interns who later spent a summer working at a large eye clinic in Kathmandu, Nepal. While there, he was amazed at the number of patients with serious eye injuries that could have been prevented with proper eyewear. So he initiated a program to collect new and gently used safety eyewear in the USA for distribution in Nepal. Working Vision continues to expand in scope and now provides eye safety programs and vision screenings, in addition to distributing safety eyewear. It’s been an honor for us to support these efforts.

Helping people regain vision and resume daily activities is an immensely rewarding endeavor. We appreciate the generous support of our donors and the dedication of our staff that makes this possible.

Sincerely,

Marianne O. Price, Ph.D.
Executive Director

A Message from the Chairman

This last year represented the 22nd year of the Cornea Research Foundation of America, and it was a year of major achievements. Achievements ranged from discovering that a new ultra-thin corneal transplant has 15 to 20 times less risk of developing a rejection episode than earlier types of corneal transplants, to for the first time, describing the proteins in the anterior part of the eye which may be responsible for causing corneas to turn cloudy after glaucoma surgery. We also were able to accumulate more revenue through donations and study-related income to fund our research activities. Since our foundation does not receive funding from the federal government, these contributions are essential for what we do.

An often used saying is that with great gifts come great responsibility, and we take our gifts very seriously. The Foundation is embarking on an ambitious research path that has the potential to dramatically change the way we approach vision correction, transplant treatments, and management of those with complicated glaucoma problems.

Because of our ongoing corneal transplant data base, the largest one in the Western Hemisphere, we can compare rejection rates between standard full thickness corneal transplants, DSEK transplants, and the new ultra-thin DMEK grafts. We recently found that the chance of having a rejection episode is 15 times less for DMEK than DSEK, and 20 less in comparison to a full thickness transplant. Topical corticosteroids, the anti-rejection drops we use after corneal transplants cause about 1/3 of patients to develop glaucoma in the first year after receiving a transplant. Since DMEK appears to have a significantly reduced rate of rejection, the Foundation is sponsoring a multi-center, international study to evaluate two different corticosteroid dosing regimens to see if we can reduce the rate of developing glaucoma without increasing the rejection rate. No one has ever done a prospective study evaluating different topical corticosteroid dosing regimens for corneal transplants even though it is the most common tissue transplant in the U.S. for over 60 years. And like all medications used with corneal transplants, it is an “off label” use of the drops – so the FDA told us we had to file for investigational drug exemption (IDE) study with them – which we have.

The Foundation is sponsoring a prospective, 3-year study with both national and international study sites evaluating patient satisfaction and visual difficulties with different vision correction methods. Other than glasses, contact lenses and Lasik are the two most common ways to correct vision. No one has ever taken on a study to evaluate how satisfied patients are with these means of visual correction and what their visual difficulties might be. Industry is reticent to do this I suspect due to liability and regulatory concerns. The government, well, they seem preoccupied with other things right now. From a public health standpoint and planning for future correction of vision, this study is very important and should lead to identification of areas of improvement for both contact lenses and Lasik. We hope to enroll between 2 and 5 thousand patients. Funding will determine the number we can enroll.

Finally, our third major area will be looking at fluid taken from the front part of the eye to help determine why some patients, like those with glaucoma filters, have damage to the endothelial cells on the inside of the cornea and to see what is happening in eyes with rejection episodes. Our hope is to develop focused, more effective treatments for both of these problems.

Each of these three studies are major undertakings, and each has the potential to make landmark changes in the way we treat diseases of the eye. Your gifts and support make all of this possible. Thank you!

Francis W. Price, Jr., MD
Founder and Chairman
The Cornea Research Foundation of America had a great year. Total revenue for the fiscal year ended June 30, 2011 was $742,510. In comparison to 2010, we saw an increase due to substantial growth in clinical study earned income. Our In-Kind Contributions were also much higher than in years' past, thanks to services generously donated by many doctors.

We are careful with our expenses, and for that reason 89% of our operating budget directly funds research and education programs.

Guidestar and the Better Business Bureau’s Wise Giving Alliance have certified that the Foundation meets their Charity Accountability Standards.

Walter C. Gross, Jr.
Treasurer

---

### Treasurers’s Report

by Walter C. Gross, Jr.

### Statements of Financial Position

**Years Ended June 30, 2011 and 2010**

<table>
<thead>
<tr>
<th>ASSETS</th>
<th>2011</th>
<th>2010</th>
</tr>
</thead>
<tbody>
<tr>
<td>CURRENT ASSETS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash and Cash Equivalents</td>
<td>320,791</td>
<td>315,246</td>
</tr>
<tr>
<td>Investments</td>
<td>165,655</td>
<td></td>
</tr>
<tr>
<td>Accounts Receivable</td>
<td>21,266</td>
<td>1,910</td>
</tr>
<tr>
<td>Total Current Assets</td>
<td>500,768</td>
<td>317,156</td>
</tr>
</tbody>
</table>

| PROPERTY AND EQUIPMENT, AT COST |        |            |
| Furniture and Equipment | 152,022  | 153,917    |

| Loss Accumulated Depreciation | (146,629) | (141,436) |
| Property and Equipment, Net   | 3,403     | 12,487     |

**TOTAL ASSETS**

| 504,890 | 529,643 |

### Liabilities and Net Assets

| CURRENT LIABILITIES |        |            |
| Accounts Payable     | 2,162   | 1,442      |
| Accrued Payroll and Other Liabilities | 31,597 | 20,962 |

**Total Current Liabilities**

| 33,749 | 22,334 |

| NET ASSETS |        |            |
| Unrestricted  | 7,500 | 257,534 |
| Temporarily Restricted | 453,740 | 295,808 |

**Total Net Assets**

| 471,240 | 307,308 |

**TOTAL LIABILITIES AND NET ASSETS**

| 504,890 | 529,643 |

---

### Statements of Activities

**Years Ended June 30, 2011 and 2010**

<table>
<thead>
<tr>
<th>REVENUE AND CONTRIBUTED SUPPORT</th>
<th>Unrestricted</th>
<th>Temporarily Restricted</th>
<th>Totals</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contributions</td>
<td>179,606</td>
<td>8,000</td>
<td>187,606</td>
</tr>
<tr>
<td>Service Related Income</td>
<td>336,324</td>
<td>9,600</td>
<td>345,924</td>
</tr>
<tr>
<td>Special Events</td>
<td>35,753</td>
<td>-</td>
<td>35,753</td>
</tr>
<tr>
<td>In-Kind Contributions</td>
<td>167,367</td>
<td>-</td>
<td>167,367</td>
</tr>
<tr>
<td>Interest Income</td>
<td>3,443</td>
<td>-</td>
<td>3,443</td>
</tr>
<tr>
<td>Other Revenue</td>
<td>537</td>
<td>537</td>
<td>1,074</td>
</tr>
<tr>
<td>Net Assets Released from Restric</td>
<td>7,600</td>
<td>(7,600)</td>
<td>-</td>
</tr>
</tbody>
</table>

**Total Revenue and Contributed Support**

| 732,510 | 10,000 | 742,510 |

**EXPENSES**

| Program Services | 515,416 | - | 515,416 |
| Supporting Services | 32,253 | - | 32,253 |
| Development       | 30,910  | - | 30,910  |

**Total Expenses**

| 578,579 | - | 578,579 |

**CHANGE IN NET ASSETS**

| 163,931 | 10,000 | 163,931 |

**NET ASSETS, BEGINNING OF YEAR**

| 298,608 | 7,600 | 307,308 |

**NET ASSETS, END OF YEAR**

| 463,740 | 17,500 | 471,240 |

**TOTAL**

| 504,890 | 529,643 |
Thank you so much for all your time, effort and professionalism during all my questions, phone calls and visits. You were awesome! It would have been impossible to decide on crosslinking without your knowledge and information you shared with me. You have a great team!

- Donna L.

Without you, we could not do what we do.
We thank our generous supporters.

**Friends (continued)**

**Gifts from $250 to $499**

Scheid Realty  
Jay and Mary Sue Schwartz  
Harold A. Sherline  
Bob Smelser  
William Stifle  
Janet and Gary Taylor  
Temp Control Service  
Jeffrey Thacker  
Trendy Trouseau LLC

**Friends**

**Gifts from $100 to $249**

- Thomas Boone
- Fred and Ellen Bosco
- Fred and Sandra Brown
- Michael Bruno
- Carmen Bullock, OD
- Timothy Buren
- James and Charlotte Butler
- Robert and Mary Ann Campbell
- Laverne and Ruth Ann Clingenpeel
- Bopp-Busch Manufacturing Company
- Mary Conners
- Marie Cormican
- Patricia Cowan
- Baker and Daniels
- Joseph Daprile
- Victor Daprile
- David and Linda Daringer
- Ted and Janet DeGarmo
- Myron and Nancy Dickerson
- Steven Doi, OD
- Harry Donovan
- Robin Felkins
- Sheila Fiala
- Timothy M. Fischer
- JP Morgan Chase Foundation
- John Frank
- William Golsmith
- Steven and Leslie Gordon
- Wayne and Marilyn Greve
- Maurice Hahn
- James and Jean Harrington
- Robert and Amy Hendricks
- Diane Hido
- Robert and Elizabeth Hiller
- David Huse, DVM
- Linda and Richard Hutchinson
- Jack Frisch & Associates
- Jostad Enterprises
- Kathy Kelley, OD
- Betty and Robert King
- Fred and Vicky Kline
- Seneca One Realty, LLC
- Dr. Alfonso Landwehr
- Jack and Joan Lane
- Judith Lasky, PhD
- Eli (Ted) Lilly II
- Guy and Arleen Lucci
- James and Theresa Maciver
- Gayle Mason
- Robert and Alana Mauzy
- Alan and Margaret McCall
- Rue and Carolyn McFarland
- Ralph Michalec
- Wendy Mickler
- Carolyn Mock
- James and Doris Morton
- Christine and Edward Muransky
- Frederic and Jane Nott
- John and Touda Oberlies
- Elizabeth Pasut
- Edwena Payne
- Albert and Audrey Pekelney
- John Peters, MD
- Angela and Francis Pierce
- Larry and Jessie Rash
- Judith A. Ratliff
- Reddington Christian Church
- Roger Reichmuth
- Jack and Joetta Riggin
- Salem Women’s Care, Inc.
- Harry W. Scheid
- Larry Sebeckis
- Judith A. Ratliff
- Reddington Christian Church
- Roger Reichmuth
- Jack and Joetta Riggin
- Salem Women’s Care, Inc.
- Harry W. Scheid
- Larry Sebeckis
- Deborah Shepherd
- James and Mary Shepherd
- Helaine Simon
- Howard Steiner
- Lester Beisner
- Virginia Belcher
- Betty Belschneider
- Stephen and Cynthia Bennett
- Julie Benson
- Mark and Michelle Billy
- Daniel and Rosemary Billicki
- Paul and Jayne Boucherle
- William W. and P.A. Bromer
- Brent Brown
- Susan Taracuk Brown
- Vincent Wagner
- Garry and Diane Warner
- Roy Michael Whetstone
- Marcus and MaryLou Winslow
- Thelma J. Woodring
- Jack and Florence Wright
- Paul Wussow
- Connie Zambelli
- Noha Khouri
- Joumana Seifeddine

**Gifts up to $99**

- Carmela Abraham
- John Arditi
- Peter and Sharon Asimakopoulos
- Neal and Suha Atey
- Mr. and Mrs. Jack J. Baker
- Lucina Barnum-Steggerda
- John and Mary Battaglia
- Howard and Carla Beeson
- Lester Beisner
- Virginia Belcher
- Betty Belschneider
- Stephen and Cynthia Bennett
- Julie Benson
- Mark and Michelle Billy
- Daniel and Rosemary Billicki
- Paul and Jayne Boucherle
- William W. and P.A. Bromer
- Brent Brown
- Susan Taracuk Brown
- Rick Bruno
- Phillip & Shirley Buchanan
- Theodora Callas
- Claire Cartmell
- Susan Cassidakis
- Harold Chambers
- Timothy and Susan Cianciola
- Linda Cline
- James and Pearlie Corbett
- Vera Cox
- Joseph and Cheryl Crum
- Billy and Natalie Cupler
- Anthony and Amy Daprile
- James Daprile
- Kimberly Davis
- Chris and Cheryl DeHoff
- Susan Domer
- Linda Eyer
- Samuel Facciobien
- James and Martha Fairchild
- Gerald Fallon
- Drew Fasseas
- John Fazzone
- Timothy and Ruth Franklin
- Margaret Freeman
- Tonya and Brian Frost
- Royce Garrett
- Cecelia Gastelum
- Karen Giorgetti
- Sydelle Golub
- William P. Goodman, III
- Brian and Melinda Governor
- Dorothy Grainger
We thank our generous supporters.

**Friends (continued)**

**Gifts up to $99**

- Thomas Green
- Donna Griesmer
- Joan Hackler
- David and Traci Hardy
- Jennifer and Paul Harris
- Max and Eldred Hauk
- Michael and Marsha Hile
- Carol Hinkle
- Dale and Jo Ann Hoepf
- Sarah Hoover
- Marceda Hosted
- Robert Hotchkiss
- Pamela Hudson
- Dorothy Ann Hummel
- John W. Hussey
- Samuel Jacobs
- David and Michelle Jakovina
- Greg Jansen
- Jaime Jarvis
- Doris M. Johmann
- Myron and Rose Jane Kaiser
- Megan and Roland Kaleel
- Carol Kalp
- Julie Kamenitsa
- Roger and Ellen Kinsey
- Michael Kovatch
- Matthew Kusy
- Joseph and Mary Jo Lenefonte
- Amanda Lopez
- Anne-Marie and Mark Luchansky
- Steven and Palan Lussier
- Neva Maloy
- Marsha Marzano
- George and Beverly Matsox
- Donnalou and Patrick McVay
- Virginia L. Merillat
- Jemilla Kidanu Michael
- Helen Miller
- Norman T. Mills
- Annabella and Dominador Miranda
- Toby and Janet Mirto
- Richard and Cherie Mize
- Kamel Muakkassa
- Joyce Nevil
- Elaine and Donald Newman
- David and Candice Niederhaus
- Richard and Nancy Novotny
- Vilma Ortiz
- Asha and Sushil Pandhi
- Martin and Teresa Papai
- Richard and Phyllis Paul
- Patricia A. Peters
- Stepheny and James Pisciuneri
- William and Debra Pisciuneri
- Richard Preske
- James and Julie Rafoth
- Lee Rasamny
- Glendolyn Rhymier
- Bessie and Melissa Rice
- Mark and Nancy Sabol
- Michael Schaub
- Kurt Schwant
- Daniel Schwartz
- Connie Shepherd
- Charles and Shirley Shoppell
- Rita Sibert
- Robert D. Sipress
- Catherine Slovan
- Marlyse Spicer
- Erwin F. Springer
- Stanich SCP
- Pamela Steinhauser
- Phil Stuart, OD
- Marilyn Sullivan
- Doris Szijj
- Joseph and Debbie Thomas
- Judith Thomas
- Tunno Insurance Agency
- Nancy and Michael Vince

**Honor and Memorial Contributions**

- Lucinda Barnum-Steggerda in honor of Robert Barnum
- Seneca One Realty, LLC in honor of Jane Kelsch
- Mary Lynn McIntyre in memory of Charlie Anne Newton

**Study Related Income**

- Alcon Laboratories
- Allergan
- Avedro
- Case Western Reserve University
- Cook Pharmaceuticals
- ISTA Pharmaceuticals
- Jaeb Center for Health Research, Inc
- Patient Education Concepts/CRM
- Trial Runners, LLC
- University of Illinois—Chicago

You help make better vision possible.
Preventing Cornea Transplant Rejection

One of the biggest risks transplant recipients face is that immunologic graft rejection will cause the new donor cornea to fail. Corticosteroid eye drops are typically used for months or even years to prevent cornea transplant rejection. Unfortunately, these eye drops have some serious side effects. Surprisingly, no prospective randomized studies have been done to determine the best corticosteroid-dosing regimen, so solid evidence on what is the best dosing for transplant patients is lacking. We have found that the new, minimally invasive transplant procedure called DMEK has a very low risk of rejection. So we have initiated a large study to see if we can reduce the topical corticosteroid strength, and avoid some of the steroid side effects, while maintaining a low risk of rejection after DMEK. We will enroll 440 patients in the study and follow each patient for one year. This landmark study will provide valuable new information to help cornea transplant recipients maintain newly restored vision.

DMEK—The Latest Advancement in Cornea Transplants

Exciting News

Decreased risk of rejection from 12 percent to less than 1 percent!

Corneas are about the thickness of a credit card and are comprised of three distinct layers. Although corneal problems are usually localized to just one or two layers, the traditional approach was to replace them all. In Figure 1 below, the arrow is pointing to a single line—this is the thickness of a cornea transplant using the DMEK technique. In Figure 2, the overall length of the red arrow represents the thickness of a full thickness transplant.

Dr. Price helped pioneer cornea transplant techniques that replace only the diseased portion of the cornea, leaving healthy layers intact. Only the ultra-thin cell layer lining the inner surface of the cornea is diseased in about half the patients who need a transplant. According to Dr. Price, “Replacement of the inner cell layer with a single cell layer from a donor cornea (a technique known as DMEK) provides much better and faster visual recovery than earlier methods.”

The reason cornea transplants fail is because the recipient’s body can recognize the donor tissue as foreign and mount an attack against it. Our research has found that single layer DMEK grafts are 15- to 20-times less likely to be rejected than earlier techniques that include two or more layers of the cornea. According to Dr. Price, “99% of our DMEK recipients remain rejection-free at two years and beyond. Having a transplant technique that can better elude rejection is a huge breakthrough for cornea transplant recipients.”
Key Research Areas

Improving Cornea Transplant Survival

Each year approximately 42,000 Americans need a transplant to replace the cornea, the clear window on the front surface of the eye. Cornea transplants usually remain clear for at least 10 years, but in some patients they fail much sooner. We are working to figure out why transplants sometimes fail early and to develop innovative treatments to extend transplant survival. We are doing this by removing and analyzing fluid from inside the eye, called the aqueous humor. The fluid bathes the back surface of the cornea and provides key nutrients that help maintain the health of the cornea. In this study we will identify the changes that occur in this fluid when a cornea transplant starts to fail. This study will provide key information needed to help maximize cornea transplant survival. We’re evaluating up to 360 subjects.

In earlier studies, we found that patients who have had glaucoma surgery are at particularly high risk for early cornea transplant failure, and we identified some intriguing changes that occur in the fluid inside the eye after glaucoma surgery. We are following up on these promising discoveries by collecting and analyzing aqueous humor samples from cornea transplant recipients who are at increased risk of graft failure either because they had prior glaucoma surgery, they had an acute immunologic graft rejection episode, or they experienced a sudden loss of cells from the back surface of the cornea for unknown reasons. Fluid samples collected from uncomplicated eyes with a previous corneal transplant serve as controls.

Vision Correction Method Study—LASIK/Contact Lenses

The Foundation is conducting a national clinical survey study comparing visual results, patient satisfaction and quality of life issues as they relate to LASIK and contact lenses. This is the first prospective study to follow these two popular methods of vision correction for nearsightedness, astigmatism, and farsightedness simultaneously.

Patient consents and surveys are conducted over the internet using a HIPAA compliant web portal that will automatically coordinate future patient surveys at the one, two and three-year anniversaries of the study date of entry.

Our goal of the study is to enroll between 2 and 5 thousand patients - both those undergoing LASIK, and patients who will continue to wear contact lenses. We will determine if visual satisfaction, visual complaints and safety – as reported by participants – are similar or different between the two groups. Study sites throughout the United States are currently enrolling patients in the study.

For a complete listing of our current studies, please visit www.cornea.org and click on Research and then Current Studies.
Award Winning Research
Drs. Price receive Santa Catarina Award in Sienna, Italy

Francis W. Price, Jr., MD and wife Marianne Price, PhD were presented with the “Santa Caterina Oro Città di Siena” International Prize on February 27, 2011 in Siena, Italy. Drs. Price traveled to Siena and were honored at the ceremony receiving the Santa Caterina gilded statue at the Teatro dei Rozzi in Siena.

Francis W. Price Jr., MD of Price Vision Group is the founder and president of the Cornea Research Foundation of America, and his wife, Marianne is the Foundation’s executive director. Together they were chosen as recipients of the Santa Caterina prize as their research has led to significant improvements in cornea transplant surgery and treatment of eye diseases around the world.

Each year, ten recipients from different areas of expertise all over the world are selected to receive this prestigious award. The Prices commented, “We feel blessed to have found better ways to give people back the use of their eyes and to have had the opportunity to share improved techniques with eye care professionals nationally and internationally.” For more information, visit http://www.cornea.org.
The Foundation would like to thank all of those who served on our **Cornea Classic Golf Committee** for organizing a successful golf outing on June 2, 2011 at Wood Wind Golf Club in Westfield, Indiana. The event raised nearly $28,000 to fund our mission to provide research and education to preserve and restore vision. Thanks to all who donated, sponsored and participated in the event. The outing will be held on **June 21, 2012** next year. If you would like to receive the registration form in February, give us a call at 317-814-2993.

Each year the Foundation sponsors an all-day seminar for optometrists that features programming on the latest treatments and surgeries available for the anterior segment of the eye and cornea. Attendees earn approved continuing education credits while learning about the newest ophthalmic medical devices, pharmaceuticals, and practice management techniques.

**Focus on Education Optometrist Seminar**

**November 2010**

**Golf Committee**

Harry W. Scheid  
Chairman

Vern Rensing  
Vice Chairman

Pat Chastain  
Mike Dickerson  
Phil Gibson  
Walter C. Gross, Jr.  
Mark Horton  
Joe Kack  
Francis W. Price, Jr.

**June 2011**

Cornea Classic Golf Outing a Success
Click on the blue hyperlinks to read each publication.


For a complete listing of our publications, please visit www.cornea.org and click on Research and then Publications.
Between July 1, 2010 and June 30, 2011

Soper M, Price MO. Eye bank preparation of DMEK tissue (DMEK with stromal ring).

**West Virginia Academy of Eye Physicians & Surgeons annual meeting**, White Sulfur Springs, WV, June 2011
Price FW, Price MO. The current state of the art in corneal crosslinking.
Price FW, Price MO. Anterior lamellar keratoplasty.
Price FW, Price MO. Evolving surgical techniques in endothelial keratoplasty.
Price MO, Price MO. Glaucome/IOP control, topical corticosteroid use, and immunologic graft rejection with endothelial keratoplasty.
Price MO, Price FW. Management of cataracts in patients with Fuchs’ dystrophy.
Price MO, Price FW. Long term endothelial keratoplasty survival and risk factors for graft failure.

**Association for Research in Vision and Ophthalmology annual meeting**, Ft. Lauderdale, FL, May 2011
Price MO, Anshu A., Price FW. Outcomes of endothelial keratoplasty under failed penetrating keratoplasty.

**American Society of Cataract and Refractive Surgery annual meeting**, San Diego CA, March 2011
Guerra F, Price MO, Price FW. Fellow eye comparison of DSAEK and DMEK. (Best Cornea poster award).
Arundhati A, Price MO, Price FW. Descemet-stripping endothelial keratoplasty survival outcomes in eyes with pre-existing glaucoma.
Guerra F, Ambrosio, R, Price MO, Price FW. Preliminary results of enhanced ectasia screening of refractive surgery patients based on corneal tomography.
Arundhati A, Price MO, Price FW. Outcomes of endothelial keratoplasty under penetrating keratoplasty.
Planchar B, Price MO, Price FW. Retained viscosurgical device as cause of interface haze after Descemet-stripping endothelial keratoplasty.
Price FW, Price MO. Setting new benchmark for LASIK.

**Societa Italiana Trapianto di Cornea annual meeting**, Bologna, Italy, February 2011
Price FW, Price MO. Ten years experience with endothelial keratoplasty. (Keynote lecture).
Price MO, Price FW. Long term visual outcomes and graft survival after DSAEK. (Keynote lecture).

**International Innovation Technology Meeting**, Mendoza Argentina, December 2010
Price FW, Price MO. New indications for corneal collagen cross linking.
Price FW, Price MO. DMEK and DMAEK: patient selection and how to optimize visual results with endothelial keratoplasty. (Keynote lecture).
Price MO, Price FW. DSAEK long-term graft survival and comparison with PKP. (Keynote lecture).
Price MO, Price FW. Impact of glaucoma on DSAEK: is it different from PKP?
Price MO, Price FW. What has been learned about graft rejection?

**Asian Cornea Society Bi-annual Meeting**, Kyoto, Japan, December 2010.
Price FW, Price MO. Endothelial Keratoplasty Overview: where are we now and where are we going? (Keynote lecture).
Price FW, Price MO. Long-term Outcomes of DSEK/DSAEK. (Keynote lecture).
Price FW, Price MO. Surgical tips for DMEK and DMAEK.
Price MO, Price FW. What have we learned about IOP control and outcomes in DSEK/DSAEK eyes with and without glaucoma?
Price MO, Price FW. Outcomes of DMEK, DMAEK, and eye bank prepared DMEK grafts.

**Cornea Society/EBAA Fall Educational Symposium**, Chicago, IL, October 2010.
Price FW, Price MO, Guerra F, Schrier A. Prospective randomized trial of cross-linking for infectious keratitis.
Guerra F, Price MO, Price FW. Fellow eyes comparison of DSAEK and DMEK.

**American Academy of Ophthalmology annual meeting**, Chicago, IL, October 2010.
Price MO, Price FW. Do Larger Descemet Stripping Endothelial Keratoplasty Grafts have Better Long-term Endothelial Cell Density? (Best poster award).

Price FW. Outcomes with Femtosecond laser assisted corneal transplants over a 4.5 year period.
Price MO, Price FW. Five year graft survival of Descemet stripping endothelial keratoplasty.
Price FW, Price MO. Prospective multi-center analysis of 1-year outcomes with DMEK.
Price FW. Cross linking for the treatment of corneal infections.
Price FW, Price MO. DSAEK: five-year results.

**Aegean Cornea Congress**, Crete, Greece, July 2010.
Price FW. Current Status of Posterior Corneal Transplantation.
Thank you for taking the time to review our 2011 Annual Report.

If you have any questions regarding the information inside, or would like to speak with someone about making a gift or volunteering in our office, please call us at 317-814-2993.

Do you receive our Focus E-Newsletter?
If you do not, and you would like to be kept up to date on our research, please email Jessica@cornea.org to be added to the mailing list.

Interested in volunteering?

No one understands the importance of better vision more than we do.

Conducting research today for brighter futures tomorrow.

WWW.CORNEA.ORG